Efficacy of behavioral therapy and different dosages of mirabegron for the treatment of male overactive bladder patients
International Urology and Nephrology · 2026
DOI: 10.1007/s11255-026-05220-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urology and Nephrology, 2026. Verfasst von You-Ting Tsai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Acetanilides, Urinary Bladder, Overactive, Thiazoles, Adrenergic beta-3 Receptor Agonists. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Taiwan Continence Society.
Abstract (Originalsprache)
PURPOSE: Behavioral therapy is the established first-line treatment for overactive bladder (OAB), followed by pharmacotherapy as the second-line intervention. Mirabegron, a β3-adrenoceptor agonist, has demonstrated comparable efficacy to antimuscarinics. This study aims to evaluate the real-world efficacy of behavioral therapy, both as a monotherapy and in combination with mirabegron, for male patients with OAB. METHODS: This pooled analysis from three studies involved 280 adult male OAB patients assigned to behavioral therapy alone or combined with mirabegron (25 mg or 50 mg) for 12 weeks. The primary outcome was the change in the Overactive Bladder Symptom Score (OABSS) from baseline to week 12. Secondary outcomes included changes in the International Prostate Symptom Score (IPSS), Patient Perception of Bladder Condition (PPBC), Quality of Life (QOL) score, maximum flow rate (Qmax), and post-void residual (PVR) volume. RESULTS: At week 12, all groups exhibited significant within-group improvements in total OABSS, with no statistically significant inter-group differences. Significant improvements were also observed in the IPSS, QOL, PPBC, urge urinary incontinence (UUI), and nocturia across all groups. Notably, behavioral therapy demonstrated substantial therapeutic potential for storage symptoms (IPSS storage sub-score), particularly regarding UUI and nocturia. No negative impacts on PVR or Qmax were observed across the three treatment arms at week 12. CONCLUSION: In real-world clinical practice, both behavioral therapy and combination therapy with varied dosages of mirabegron effectively alleviate OAB symptoms in male patients without compromising voiding function. Beyond conventional pharmacotherapy, optimizing the role of behavioral therapy remains a fundamental component of comprehensive OAB management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan. doristou@ms31.hinet.net.
Förderung
- Taiwan Continence Society
Zitieren
APA
Tsai, Y. T., Chuang, Y. C., Wang, H. J., Lee, W. C., & Shen, Y. C. (2026). Efficacy of behavioral therapy and different dosages of mirabegron for the treatment of male overactive bladder patients. International Urology and Nephrology. https://doi.org/10.1007/s11255-026-05220-2
Vancouver
Tsai YT, Chuang YC, Wang HJ, Lee WC, Shen YC. Efficacy of behavioral therapy and different dosages of mirabegron for the treatment of male overactive bladder patients. International Urology and Nephrology. 2026. doi:10.1007/s11255-026-05220-2
BibTeX
@article{Tsai2026,
author = {Tsai, You-Ting and Chuang, Yao-Chi and Wang, Hung-Jen and Lee, Wei-Chia and Shen, Yuan-Chi},
title = {Efficacy of behavioral therapy and different dosages of mirabegron for the treatment of male overactive bladder patients},
journal = {International Urology and Nephrology},
year = {2026},
doi = {10.1007/s11255-026-05220-2}
}
EUVIMED